Search - tctmd.com

Displaying 21 - 40 of 93

Sort: Relevancy | Date

News Opinion CV Team Dispatch

June 2021 News Roundup

L.A. McKeown

June 01, 2021

News Conference News ACC 2021

SAFE-PAD Throws More Doubt on the Paclitaxel Mortality Signal

L.A. McKeown

May 16, 2021

News Daily News

Vascular Experts Say It’s Time to Let Paclitaxel Out of Regulatory Jail

L.A. McKeown

April 22, 2021

FDA Says Newer Paclitaxel Data Is ‘Comforting’ but Limited

News Daily News

FDA Says Newer Paclitaxel Data Are ‘Comforting’ but Limited

L.A. McKeown

January 12, 2021

News Conference News VIVA 2020

DISRUPT PAD III: Lithotripsy Shows Promise in Heavily Calcified PAD

L.A. McKeown

November 09, 2020

Direct Temsirolimus Delivery Shows Promise in BTK: Phase II Study

News Conference News TCT 2020

Direct Temsirolimus Delivery Promising in BTK: TANGO Phase II Study

Caitlin E. Cox

October 18, 2020

News Daily News

No Long-term Mortality Risk for Paclitaxel-Based Peripheral Devices: Medicare Advantage Cohort

L.A. McKeown

June 29, 2020

News Conference News LINC 2020

Algorithm Aims to Help Operators Pair Laser Settings With PAD Lesion Type

L.A. McKeown

February 06, 2020

News Conference News LINC 2020

DCBs Show Consistent Long-term Benefits in Complex Fem-Pop Patient Subsets

L.A. McKeown

January 30, 2020

News Conference News LINC 2020

Lutonix BTK Studies: Below-the-Knee Challenges Linger

L.A. McKeown

January 29, 2020

News Conference News ISET 2020

FDA’s First Take on New Paclitaxel Concerns in CLI

Caitlin E. Cox

January 24, 2020

News Daily News

Paclitaxel DCBs Now Implicated in Death, Amputation in Below-the-Knee CLI

L.A. McKeown

January 15, 2020

News Industry News

Boston Scientific Responds to the FDA’s Guidance on Use of Peripheral Paclitaxel Devices for Treatment of PAD

August 07, 2019

News Daily News

DCB Match DES Through 1 Year in Femoropopliteal Lesions, DRASTICO Affirms

Caitlin E. Cox

July 11, 2019

News Daily News

FDA Review Affirms Mortality Signal With Paclitaxel-Based Devices for PAD Ahead of Panel Meeting

L.A. McKeown

June 10, 2019

News Conference News EuroPCR 2019

EFFPAC: Novel Paclitaxel DCB for PAD Demonstrates Efficacy With No Mortality Signal

L.A. McKeown

May 23, 2019

News Daily News

FDA Analysis Points to Higher Death Risk With Paclitaxel-Based Devices for PAD

L.A. McKeown

March 15, 2019

News Conference News CRT 2019

SAFE-DCB Demonstrates Consistent Efficacy at 1 Year in Real-world Femoropopliteal Disease Patients

Yael L. Maxwell

March 14, 2019

News Conference News CRT 2019

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

L.A. McKeown

March 06, 2019

News Conference News ISET 2019

Eluvia Sustains Lead Over Zilver PTX in Patients With Diabetes: IMPERIAL Subanalysis

Caitlin E. Cox

January 30, 2019

Advertisement

June 2021 News Roundup

SAFE-PAD Throws More Doubt on the Paclitaxel Mortality Signal

Vascular Experts Say It’s Time to Let Paclitaxel Out of Regulatory Jail

FDA Says Newer Paclitaxel Data Are ‘Comforting’ but Limited

DISRUPT PAD III: Lithotripsy Shows Promise in Heavily Calcified PAD

Direct Temsirolimus Delivery Promising in BTK: TANGO Phase II Study

No Long-term Mortality Risk for Paclitaxel-Based Peripheral Devices: Medicare Advantage Cohort

Algorithm Aims to Help Operators Pair Laser Settings With PAD Lesion Type

DCBs Show Consistent Long-term Benefits in Complex Fem-Pop Patient Subsets

Lutonix BTK Studies: Below-the-Knee Challenges Linger

FDA’s First Take on New Paclitaxel Concerns in CLI

Paclitaxel DCBs Now Implicated in Death, Amputation in Below-the-Knee CLI

Boston Scientific Responds to the FDA’s Guidance on Use of Peripheral Paclitaxel Devices for Treatment of PAD

DCB Match DES Through 1 Year in Femoropopliteal Lesions, DRASTICO Affirms

FDA Review Affirms Mortality Signal With Paclitaxel-Based Devices for PAD Ahead of Panel Meeting

EFFPAC: Novel Paclitaxel DCB for PAD Demonstrates Efficacy With No Mortality Signal

FDA Analysis Points to Higher Death Risk With Paclitaxel-Based Devices for PAD

SAFE-DCB Demonstrates Consistent Efficacy at 1 Year in Real-world Femoropopliteal Disease Patients

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

Eluvia Sustains Lead Over Zilver PTX in Patients With Diabetes: IMPERIAL Subanalysis

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content